fosfomycin trometamol — ‘a biopharmaceutical improvement’
TRANSCRIPT
20 PHARMACOLOGY
Fosfomycin trometamol-'a biophannaceutical improvement'
Treatment with oral fosfomycin trometamol 2, 3, and 4g 'copen for key urinary tract pathogens for 24-48 h and at least 36 h with the 3 g oral dose' according to the results of a pharmacokinetic study by Professor T Bergen from Norway, and colleagues.
The bioavailability of fosfomycin trometamol in the present study of 12 healthy volunteers was 33%, compared with a bioavailability of 12% for the calcium salt of fosfomycin found in a previous study by Professor Bergen. Thus, 'there is no doubt that the trometamol salt represents a biopharmaceutical impropement', say Bergen and colleagues, although other studies have found 28 and 37% bioavailability for the calcium salt.
In the present study, the maximum concentration of fosfomycin trometamol and the AUe appeared to be directly proportional to the oral dose administered, but the elimination half-life was not dose-dependent. Bergan T. Thorsteinsson SB. Albini E. Pbannacoldnetic profile of fosfomycin trometarnol. Chemotherapy (Basel) 39: 297·301. Sep-Oct 1993
1!IOO217164
4 Sep 1993INPHARMAe ISSN 0156-270319310904-00201$1 .ex!' Adla IntematIoNIl Ltd